Results 171 to 180 of about 5,563 (240)

Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager. [PDF]

Mol Ther Oncol
Choi MJ, So EY, Akosman B, Lee YE, Raufi AG, Reginato AM, Chen CC, Lawler SE, Wong ET, Liang OD.   +9 more
europepmc   +1 more source

Vaccine-educated T cells and a CD123 bispecific T-cell engager for treatment of acute myeloid leukemia. [PDF]

Blood Adv
Liegel J, Stroopinsky D, Cheloni G, Karagkouni D, Nahas M, Ma Y, Torres D, Saldarriaga I, Wang S, Arruda de Amaral A, Ploumakis A, Clohessy J, Abirached J, Bisharat L, Fraenkel P, Yildirim O, Bonnevaux H, Guerif S, Rallis K, Chedid G, Kufe D, Vlachos IS, Avigan D, Rosenblatt J.   +23 more
europepmc   +1 more source

Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy. [PDF]

Signal Transduct Target Ther, 2023
Yang XM, Lin XD, Shi W, Xie SX, Huang XN, Yin SH, Jiang XB, Hammock BD, Xu ZP, Lu XL.   +9 more
europepmc   +1 more source

A KRAS^G12V-targeted bispecific T cell engager promotes immunity against colorectal solid tumor. [PDF]

Mol Ther Oncol
Huynh N, Nguyen TT, Bui NT, Nguyen HN, Nguyen CT.   +4 more
europepmc   +1 more source

Safety and Practicalities of Bispecific T-Cell Engager Administration in a District General Hospital Setting. [PDF]

EJHaem
Lau B, Gabrie S, Hobbs P, Newman J, Elzein A, Sargant N, Cowley A, Nikolova A, Flanagan C, Burt L, Saddleton M, Evans C, Street T, Mahbak H, Lazaro A, Grace R, Jones JR.   +16 more
europepmc   +1 more source

Unleashing the potential of bimetallic nanobomb-mediated STING pathway to enhance bispecific T-cell engager against colorectal cancer photo-immunotherapy. [PDF]

Signal Transduct Target Ther
Mu M, Li H, Chen B, Fan R, Zhong K, Wang G, Feng C, Chen N, Guo G, Tong A, Zou B.   +10 more
europepmc   +1 more source

Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab. [PDF]

Leuk Lymphoma, 2023
Parisi R, Cowen EA, Gu S, Dusza S, Pulitzer M, Geyer MB, King AC, Markova A.   +7 more
europepmc   +1 more source

Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation [PDF]

Leukemia, 2018
Colin E. Correnti, George S. Laszlo, Willem J. de van der Schueren, Colin D. Godwin, Ashok Bandaranayake, Melanie A. Busch, Chelsea J. Gudgeon, Olivia M. Bates, James M. Olson, Christopher Mehlin, Roland B. Walter   +10 more
openaire   +2 more sources

Organ-specific delivery of an mRNA-encoded bispecific T cell engager targeting glypican-3 in hepatocellular carcinoma. [PDF]

Nat Commun
Huang Y, Liu S, Zhang X, Zhang B, Shi F, Zhang J, Shao S, Han H, Ma X, Xie J, Zhang J, Yu H, Zhao Y, Jin J, Xu D, Liu L, Wang J, Tan Y, Xu K, Jin L, Du Q, Geng Y, Liu A, Xu W.   +23 more
europepmc   +1 more source

Protracted viral infections in patients with multiple myeloma receiving bispecific T-cell engager therapy targeting B-cell maturation antigen. [PDF]

Haematologica, 2023
Palmen B, Hari P, D'Souza A, Abid MB.
europepmc   +1 more source